Here's a mix of stories from the past few days.
Amgen emerged victorious over Roche in its five-year battle over the anti-anemia drug, Mircera - a pegylated-EPO. Roche acknowledged that its version of the drug infringed the Amgen patent. Full text.
Teva settles several civil suits that related to drug price reporting by manufacturers in 15 states. The suits alleged that prices reported to government were resulting in inflated payments under Medicaid. Teva denied allegations but agreed to settle. Full text.
BIO addressed open letter to HHS expressing concerns about recommendations by the Secretary's Advisory Committe on Genetics, Health and Society (SACGHS) that would weaken value of gene-based patents. Implementation of these recommendations according to BIO and its stakeholders would weaken patent law and be counter to the intent of Bayh-Dole Act meant to encourage biotech investment. Read more in GEN, , and Biotech Patent Blog. The full text of the BIO letter.
Posted by Bruce Lehr Feb 6, 2010